MX390494B - UNA NUEVA SUBPOBLACIÓN DE TREGS CD8+CD45RCbajo Y SUS USOS. - Google Patents
UNA NUEVA SUBPOBLACIÓN DE TREGS CD8+CD45RCbajo Y SUS USOS.Info
- Publication number
- MX390494B MX390494B MX2018002849A MX2018002849A MX390494B MX 390494 B MX390494 B MX 390494B MX 2018002849 A MX2018002849 A MX 2018002849A MX 2018002849 A MX2018002849 A MX 2018002849A MX 390494 B MX390494 B MX 390494B
- Authority
- MX
- Mexico
- Prior art keywords
- cd45rclow
- tregs
- new subpopulation
- subpopulation
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306366 | 2015-09-07 | ||
| PCT/EP2016/070991 WO2017042170A1 (en) | 2015-09-07 | 2016-09-06 | A new subpopulation of cd8+cd45rclow tregs and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018002849A MX2018002849A (es) | 2018-09-05 |
| MX390494B true MX390494B (es) | 2025-03-20 |
Family
ID=54196910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002849A MX390494B (es) | 2015-09-07 | 2016-09-06 | UNA NUEVA SUBPOBLACIÓN DE TREGS CD8+CD45RCbajo Y SUS USOS. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180251731A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3347452B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2018527932A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102768442B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108291203A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016318762B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018004454A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2997646C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2890818T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL257891B (cg-RX-API-DMAC7.html) |
| MX (1) | MX390494B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017042170A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201801265B (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3042179A1 (en) * | 2016-10-31 | 2018-05-03 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene |
| EP4417210A1 (en) | 2017-03-15 | 2024-08-21 | Orca Biosystems, Inc. | Compositions and methods for hematopoietic stem cell transplants |
| EP3652306A1 (en) | 2017-07-13 | 2020-05-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs |
| WO2019141774A1 (en) * | 2018-01-19 | 2019-07-25 | Miltenyi Biotec Gmbh | Regulatory t cell expressing a chimeric antigen receptor |
| EP3749334B1 (en) | 2018-02-08 | 2024-12-11 | The Board of Trustees of the Leland Stanford Junior University | Allogenic hematopoietic stem cell transplantation |
| CN111936180B (zh) * | 2018-03-14 | 2024-04-05 | 热动力医疗公司 | 浮力激活细胞分选(bacs)兼容的激活/转导系统和方法 |
| AU2019378883A1 (en) | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for T cell delivery |
| EP3894543A1 (en) * | 2018-12-14 | 2021-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs |
| MX2021013227A (es) * | 2019-04-30 | 2022-01-06 | Univ California | Expansion ex-vivo sin microesferas de celulas t reguladoras humanas. |
| AU2020327949A1 (en) * | 2019-08-14 | 2022-03-03 | The Regents Of The University Of California | CAR-T cells specific for modified proteins in extracellular spaces |
| WO2024028486A1 (en) * | 2022-08-04 | 2024-02-08 | Nantes Universite | In vitro method for obtaining clinical-grade cd8+ cd45rclow/- regulatory t cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001253400B2 (en) * | 2000-04-11 | 2007-03-01 | University Of Southern California | A method to prevent graft rejection using tgf-beta to induce t suppressor cells |
| EP2126054B1 (en) * | 2007-01-31 | 2016-07-06 | Yeda Research And Development Company Limited | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| ES2702676T3 (es) * | 2014-04-01 | 2019-03-04 | Inst Nat Sante Rech Med | Péptido de donante aislado derivado de MHC y usos del mismo |
| US10155025B2 (en) * | 2014-07-17 | 2018-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for inhibiting or reducing transplant rejection by adminstration of interleukin-34 |
-
2016
- 2016-09-06 JP JP2018511706A patent/JP2018527932A/ja active Pending
- 2016-09-06 AU AU2016318762A patent/AU2016318762B2/en active Active
- 2016-09-06 CN CN201680064881.0A patent/CN108291203A/zh active Pending
- 2016-09-06 US US15/758,139 patent/US20180251731A1/en not_active Abandoned
- 2016-09-06 CA CA2997646A patent/CA2997646C/en active Active
- 2016-09-06 KR KR1020187009677A patent/KR102768442B1/ko active Active
- 2016-09-06 WO PCT/EP2016/070991 patent/WO2017042170A1/en not_active Ceased
- 2016-09-06 MX MX2018002849A patent/MX390494B/es unknown
- 2016-09-06 ES ES16769882T patent/ES2890818T3/es active Active
- 2016-09-06 EP EP16769882.8A patent/EP3347452B1/en active Active
- 2016-09-06 BR BR112018004454A patent/BR112018004454A2/pt not_active Application Discontinuation
-
2018
- 2018-02-23 ZA ZA2018/01265A patent/ZA201801265B/en unknown
- 2018-03-05 IL IL257891A patent/IL257891B/en active IP Right Grant
-
2021
- 2021-08-18 JP JP2021133065A patent/JP7254128B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016318762A1 (en) | 2018-03-22 |
| RU2766691C2 (ru) | 2022-03-15 |
| JP7254128B2 (ja) | 2023-04-07 |
| CN108291203A (zh) | 2018-07-17 |
| BR112018004454A2 (pt) | 2018-09-25 |
| US20180251731A1 (en) | 2018-09-06 |
| IL257891A (en) | 2018-05-31 |
| KR102768442B1 (ko) | 2025-02-17 |
| RU2018107363A (ru) | 2019-10-09 |
| ZA201801265B (en) | 2022-08-31 |
| IL257891B (en) | 2020-09-30 |
| ES2890818T3 (es) | 2022-01-24 |
| JP2018527932A (ja) | 2018-09-27 |
| WO2017042170A1 (en) | 2017-03-16 |
| EP3347452A1 (en) | 2018-07-18 |
| NZ740225A (en) | 2025-05-30 |
| CA2997646A1 (en) | 2017-03-16 |
| EP3347452B1 (en) | 2021-06-23 |
| MX2018002849A (es) | 2018-09-05 |
| JP2021183631A (ja) | 2021-12-02 |
| AU2016318762B2 (en) | 2022-03-31 |
| RU2018107363A3 (cg-RX-API-DMAC7.html) | 2020-02-27 |
| CA2997646C (en) | 2024-04-23 |
| KR20180054663A (ko) | 2018-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390494B (es) | UNA NUEVA SUBPOBLACIÓN DE TREGS CD8+CD45RCbajo Y SUS USOS. | |
| ECSP18040758A (es) | Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos | |
| MX2022013540A (es) | Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica. | |
| TWD190312S (zh) | 項鍊 | |
| MX375352B (es) | Reguladores de nrf2. | |
| TWD177948S (zh) | 垂飾 | |
| TWD181261S (zh) | 項鍊 | |
| TWD182272S (zh) | 項鍊 | |
| TWD178825S (zh) | 項鍊 | |
| CR20170240A (es) | Anticuerpos anti-interleucina-33 y sus usos | |
| TWD170353S (zh) | 項鍊 | |
| CL2019002605A1 (es) | Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas. | |
| TWD174683S (zh) | 戒指 | |
| MA40579A (fr) | Anticorps anti-cll-1 et immunoconjugués | |
| MA51107A (fr) | Cellules souches et progénitrices hématopoïétiques humaines cd34+ modifiées par crispr-cas9 et utilisations associées | |
| TWD176022S (zh) | 項鍊 | |
| TWD191607S (zh) | 無人機 | |
| MX2017002469A (es) | Composiciones de matrices extracelulares. | |
| MX389001B (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| TWD194965S (zh) | 無人機 | |
| MX2018007390A (es) | Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo. | |
| MX377774B (es) | Formulaciones de proteinas. | |
| MX2017015315A (es) | Granos de gluten reducido y composiciones de los mismos. | |
| MX382864B (es) | Formulaciones de anticuerpos cristalinos. | |
| MX2016016233A (es) | Anticuerpos anti-lgr5 y sus usos. |